Fabrication of acetylated carboxymethylcellulose coated hollow mesoporous silica hybrid nanoparticles for nucleolin targeted delivery to colon adenocarcinoma

•Doxorubicin (DOX) was loaded into hollow mesoporous silica nanoparticles (HMSNs) coated with acetylated carboxymethylcellulose (Ac-CMC).•The drug was released in a sustained pattern with higher release rate in acidic pH.•DOX loaded AC-CMC/HMSN nanoparticles were decorated with AS1411 aptamer to spe...

Full description

Saved in:
Bibliographic Details
Published in:Carbohydrate polymers 2018-10, Vol.197, p.157-166
Main Authors: Nejabat, Mojgan, Mohammadi, Marzieh, Abnous, Khalil, Taghdisi, Seyed Mohammad, Ramezani, Mohammad, Alibolandi, Mona
Format: Article
Language:English
Subjects:
Acetylated carboxymethyl cellulose
AS1411
Doxorubicin
Hollow mesoporous silica nanoparticles
Targeted drug delivery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Doxorubicin (DOX) was loaded into hollow mesoporous silica nanoparticles (HMSNs) coated with acetylated carboxymethylcellulose (Ac-CMC).•The drug was released in a sustained pattern with higher release rate in acidic pH.•DOX loaded AC-CMC/HMSN nanoparticles were decorated with AS1411 aptamer to specifically target nucleolin overexpressing cancer cells.•Aptamer conjugated AC-CMC/HMSN nanoparticles could efficiently inhibit tumorigenesis in vitro and in vivo. To efficiently deliver the chemotherapeutics to the tumor tissue and minimize the associated adverse effects, nucleolin targeted hybrid nanostructure based on hollow mesoporous silica nanoparticles (HMSNs) were fabricated. To provide the controlled, sustained drug release and enhance blood circulation, the surface of doxorubicin-encapsulated HMSNs were coated with acetylated carboxymethyl cellulose (Ac-CMC) and then covalently conjugated to AS1411 aptamer for guided drug delivery to nucleolin overexpressed cancerous cells. In vitro cellular uptake and cytotoxicity studies confirmed that AS1411 aptamer specifically targets nucleolin overexpressing MCF-7 and C26 cells. Moreover, the in vivo tumor inhibitory effect of AS1411 aptamer conjugated formulation demonstrated a superior therapeutic efficiency over non-targeted formulation and free doxorubicin. The current study might open a new insight to the development of targeted intelligent hybrid materials based on AcCMC-coated HMSNs with high loading capacity, smart characteristics and desirable anticancer potential.
ISSN:0144-8617
1879-1344
DOI:10.1016/j.carbpol.2018.05.092